Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 3 7Phase 1/2 6Phase 1 4Phase EARLY_PHASE1 2Phase 4 1

Status

Completed 2Active not recruiting 2

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Neoplasms 13Carcinoma, Hepatocellular 7Carcinoma, Renal Cell 4Lymphoma 3Endometrial Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Lymphoma, Non-Hodgkin 2Liver Neoplasms 2Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Breast Neoplasms 2Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1

Interventions

pembrolizumab 47Nivolumab 34Sunitinib 18Cyclophosphamide 18Everolimus 17Ipilimumab 15cabozantinib 14pazopanib 13Bevacizumab 13fludarabine 12atezolizumab 11temsirolimus 10Magnetic Resonance Spectroscopy 10Sorafenib 9aldesleukin 8Specimen Handling 8Paclitaxel 8Sirolimus 7CTLA-4 Antigen 7Axitinib 7belzutifan 6Radiosurgery 6Oxaliplatin 6Interleukin-2 6Fluorouracil 6spartalizumab 5avelumab 5Leucovorin 5Irinotecan 5Docetaxel 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Renal Cell × lenvatinib × Clear all
NCT05030506 2025-12-18

MK-6482-010

Merck Sharp & Dohme LLC

Phase 1 Active not recruiting
45 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT04522323 2025-07-25

A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma

MedImmune LLC

Phase 1 Active not recruiting
67 enrolled
Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell

NCT03324373 2025-04-24

Lenvatinib and Everolimus in Renal Cell Carcinoma (RCC)

University of Iowa

Phase 1 Completed
11 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT02454478 2019-03-19

Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

Eisai Inc.

Phase 1 Completed
7 enrolled 17 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡